SHAREHOLDER ALERT: FENC NXTC RETA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 22, 2020 /The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=10397&wire=1
Lead Plaintiff Deadline: November 2, 2020
Class Period: February 11, 2020 - August 10, 2020
Allegations against FENC include that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Nextcure, Inc. (NASDAQ:NXTC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/nextcure-inc-loss-submission-form?prid=10397&wire=1
Lead Plaintiff Deadline: November 20, 2020
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/reata-pharmaceuticals-inc-loss-submission-form?prid=10397&wire=1
Lead Plaintiff Deadline: December 14, 2020
Class Period: October 15, 2019 - August 7, 2020
Allegations against RETA include that: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE:The Law Offices of Vincent Wong
View source version on accesswire.com:
© 2020 Accesswire. All Rights Reserved.